Financial Report: Johnson & Johnson 2Q

Johnson & Johnson 2Q

2Q Revenues: $15.2 billion (-7%)

2Q Earnings: $3.2 billion (-4%)

YTD Revenues: $30.3 billion (-7%)

YTD Earnings: $6.7 billion (-3%)

Comments: Worldwide pharmaceutical sales were $5.5 billion in the quarter (-13%), including a 5% negative impact from currency. Domestic sales were down 16% and international sales were down 9%, the latter of which reflected an operational increase of 3% but a negative currency impact of 12%. Remicade sales were $1.1 billion (+24%). Sales of Prezista were $140 million (+59%). Velcade sales were $229 million (+12%) and Concerta sales were $317 million (+14%). Sales of Topamax and Risperdal were down 73% and 66%, respectively, due to generic competition.